One Capital Management LLC Purchases 28,433 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

One Capital Management LLC lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 61.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,973 shares of the biopharmaceutical company’s stock after purchasing an additional 28,433 shares during the period. One Capital Management LLC owned 0.06% of Catalyst Pharmaceuticals worth $1,750,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Public Sector Pension Investment Board grew its position in Catalyst Pharmaceuticals by 10.8% during the third quarter. Public Sector Pension Investment Board now owns 516,745 shares of the biopharmaceutical company’s stock worth $10,180,000 after buying an additional 50,343 shares in the last quarter. American Century Companies Inc. grew its position in Catalyst Pharmaceuticals by 43.8% during the third quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock worth $49,805,000 after buying an additional 770,198 shares in the last quarter. Rafferty Asset Management LLC grew its position in Catalyst Pharmaceuticals by 64.1% during the third quarter. Rafferty Asset Management LLC now owns 157,044 shares of the biopharmaceutical company’s stock worth $3,094,000 after buying an additional 61,328 shares in the last quarter. Royce & Associates LP grew its position in Catalyst Pharmaceuticals by 28.6% during the third quarter. Royce & Associates LP now owns 2,034,965 shares of the biopharmaceutical company’s stock worth $40,089,000 after buying an additional 452,103 shares in the last quarter. Finally, Fundsmith LLP grew its position in Catalyst Pharmaceuticals by 24.2% during the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after buying an additional 654,721 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on CPRX shares. Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Finally, HC Wainwright downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $35.00 to $31.50 in a research report on Thursday, May 28th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $31.28 on Thursday. The stock’s fifty day moving average price is $28.13 and its two-hundred day moving average price is $25.23. The company has a market cap of $3.83 billion, a PE ratio of 17.98, a P/E/G ratio of 0.95 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $32.56.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).